AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Imfinzi (durvalumab) by Year
Imfinzi (durvalumab) — Established RoW YoY actual (%) (%)
AstraZeneca Imfinzi (durvalumab): -2.0% in FY2025, up 6.0 pts from a year earlier.
Latest, FY2025
-2.0%
Period ended Dec 31, 2025
Change on a year earlier
+6.0 pts
-8.0% in FY2024
History
5 years
Since FY2020
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Imfinzi | 6,063 | 29 | 28 | 3,509 | 35 | 640 | 34 | 38 | 1,239 | 31 | 26 | 675 | (2) | (2)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Imfinzi (durvalumab) — Established RoW YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2.0% | +6.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | -8.0% | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | -1.0% | -24.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 23.0% | -28.0 pts | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 51.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Imfinzi (durvalumab) (%), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-imfinzi-erow-act-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.